Daniel L.

About Daniel L.

Seasoned MBA pharma leader with deep expertise across Specialty Care, Biotech, Vaccines, and Orphan Drugs. I specialize in Strategy and Market Access and Pricing, with a proven Global track record of expanding access, driving price and value creation, and enabling long‑term brand protection.I bring launch excellence and lifecycle impact through complex payer negotiations, evidence generation, and digital enablement, translating scientific and economic value into sustainable and growing patient access. Known as a trusted strategic partner and leader.Recognized for strong leadership, collaboration, and communication, I thrive at the intersection of strategy, business impact, and execution in highly complex market environments.

Experience

1. Global Market Access Cross-indication Immunology, Team Lead (Sr Director)

   Sanofi

   Jul 2025 — Present · Boston, MA, US

   Global Market Access and Pricing leader for complex immunology multi-indication assets, including Dupixent and Kevzara, operating across Global, Regional, and Local levels in 50+ countries. The role sits at the center of business‑critical senior decision‑making, where access, pricing, and lifecycle strategies directly shape patient reach, franchise value, and long‑term sustainability.Bring cross‑indication and cross‑franchise expertise, leading high‑stakes negotiations, launch readiness, LCM, and value protection and differentiation across both G10 and ex‑G10 markets. Focused on optimizing and safeguarding franchise value while enabling durable, differentiated access in increasingly constrained environments.Recognized for solving complex strategic and financial challenges by combining rigorous analytics with clear, compelling narratives—reshaping strategies, influencing direction, and proactively mitigating risk to preserve price integrity and business stability.Leads capability building and digital/AI transformation, modernizing ways of working to accelerate execution, improve efficiency, and deliver forward‑looking solutions. Builds high‑trust, high‑performance teams through transparency, early challenge, and continuous learning.Serve as a trusted strategic partner, translating insight into action and connecting access and pricing decisions to patient outcomes, payer expectations, and sustainable business impact.

Education

• Harvard University

  Leadership Program for Health Leaders, Public Health

  2014 — 2014

• Texas McCombs School of Business

  MBA

  2014 — 2016

• Instituto Tecnológico Autónomo de México

  Bs., Economics

  2002 — 2006